Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis

Overview

Journal Chem Rev

Publisher American Chemical Society

Specialty Chemistry

Date 2014 Nov 4

PMID 25365529

Citations 107

Authors

Advait S Nagle

Shilpi Khare

Arun Babu Kumar

Frantisek Supek

Andriy Buchynskyy

Casey J N Mathison

Naveen Kumar Chennamaneni

Nagendar Pendem

Frederick S Buckner

Michael H Gelb

Valentina Molteni

Affiliations

Soon will be listed here.

Citing Articles

Targeting Cutaneous Leishmaniasis with Thiadiazine Thione Derivatives: An In Vivo Study of Its Anti-Inflammatory, Anti-Pyretic, Anti-Nociceptive, and Anti-Sedative Properties.

Sarwar S, Sarwar N, Ali H, Rafiullah , Khan R, Ahmad A Biomedicines. 2025; 13(1).

PMID: 39857677 PMC: 11763098. DOI: 10.3390/biomedicines13010093.

Computational screening and molecular dynamics of natural compounds targeting the SH2 domain of STAT3: a multitarget approach using network pharmacology.

Kumar S, Kumar B, Nayak R, Pandey S, Kumar N, Pai K Mol Divers. 2025; .

PMID: 39786519 DOI: 10.1007/s11030-024-11075-5.

Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.

Zhang H, Yan R, Liu Y, Yu M, He Z, Xiao J PLoS Negl Trop Dis. 2025; 19(1):e0012735.

PMID: 39752369 PMC: 11698350. DOI: 10.1371/journal.pntd.0012735.

Synthesis and biological evaluation of 4,7,9-trisubstituted benzoxazepines as antileishmanial agents.

Kadayat T, Kwiatkowski S, Ortiz D, Shoeran G, Hammill J, Kim H Bioorg Med Chem Lett. 2024; 114:130003.

PMID: 39477128 PMC: 11623309. DOI: 10.1016/j.bmcl.2024.130003.

Exploring 7β-amino-6-nitrocholestens as COVID-19 antivirals: , synthesis, evaluation, and integration of artificial intelligence (AI) in drug design: assessing the cytotoxicity and antioxidant activity of 3β-acetoxynitrocholestane.

Shahabuddin , Uzma , Azam M, Parveen M, Kadir N, Min K RSC Med Chem. 2024; .

PMID: 39430952 PMC: 11485945. DOI: 10.1039/d4md00257a.

References

Berman J . Recent Developments in Leishmaniasis: Epidemiology, Diagnosis, and Treatment. Curr Infect Dis Rep. 2004; 7(1):33-38. DOI: 10.1007/s11908-005-0021-1. View

Brown M, Noursadeghi M, Boyle J, Davidson R . Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005; 153(1):203-5. DOI: 10.1111/j.1365-2133.2005.06670.x. View

Prata A . TREATMENT OF KALA-AZAR WITH AMPHOTERICIN B. Trans R Soc Trop Med Hyg. 1963; 57:266-8. DOI: 10.1016/0035-9203(63)90183-4. View

Thakur C, Kumar K . Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian J Med Res. 1990; 91:144-8. View

Roldos V, Nakayama H, Rolon M, Montero-Torres A, Trucco F, Torres S . Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies. Eur J Med Chem. 2008; 43(9):1797-807. DOI: 10.1016/j.ejmech.2007.11.007. View

Brand S, Cleghorn L, McElroy S, Robinson D, Smith V, Hallyburton I . Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem. 2011; 55(1):140-52. PMC: 3256935. DOI: 10.1021/jm201091t. View

Sundar S, Thakur B, Tandon A, Agrawal N, Mishra C, Mahapatra T . Clinicoepidemiological study of drug resistance in Indian kala-azar. BMJ. 1994; 308(6924):307. PMC: 2539260. DOI: 10.1136/bmj.308.6924.307. View

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Cook G . Leonard Rogers KCSI FRCP FRS (1868-1962) and the founding of the Calcutta School of Tropical Medicine. Notes Rec R Soc Lond. 2006; 60(2):171-81. DOI: 10.1098/rsnr.2006.0146. View

10.

Ogungbe I, Ng J, Setzer W . Interactions of antiparasitic alkaloids with Leishmania protein targets: a molecular docking analysis. Future Med Chem. 2013; 5(15):1777-99. DOI: 10.4155/fmc.13.114. View

11.

Khandpur S, Ramam M, Sharma V, Salotra P, Singh M, Malhotra A . Nerve involvement in Indian post kala-azar dermal leishmaniasis. Acta Derm Venereol. 2004; 84(3):245-6. DOI: 10.1080/00015550410024607. View

12.

Salih N, van Griensven J, Chappuis F, Antierens A, Mumina A, Hammam O . Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?. Trop Med Int Health. 2014; 19(2):146-52. DOI: 10.1111/tmi.12238. View

13.

Riente R, Souza V, Carvalho S, Kaiser M, Brun R, da Silva E . Leishmanicidal activity of new megazol derivatives. Med Chem. 2009; 5(4):392-7. DOI: 10.2174/157340609788681467. View

14.

Tuntiwechapikul W, David W, Kumar D, Salazar M, Kerwin S . DNA modification by 4-aza-3-ene-1,6-diynes: DNA cleavage, pH-dependent cytosine-specific interactions, and cancer cell cytotoxicity. Biochemistry. 2002; 41(16):5283-90. DOI: 10.1021/bi025535e. View

15.

Pereira I, Marques M, Pavan A, Codonho B, Barbieri C, Beijo L . Leishmanicidal activity of benzophenones and extracts from Garcinia brasiliensis Mart. fruits. Phytomedicine. 2009; 17(5):339-45. DOI: 10.1016/j.phymed.2009.07.020. View

16.

Shen T, Wang X, Lou H . Natural stilbenes: an overview. Nat Prod Rep. 2009; 26(7):916-35. DOI: 10.1039/b905960a. View

17.

Nagle A, Hur W, Gray N . Antimitotic agents of natural origin. Curr Drug Targets. 2006; 7(3):305-26. DOI: 10.2174/138945006776054933. View

18.

Ritmeijer K, Dejenie A, Assefa Y, Hundie T, Mesure J, Boots G . A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis. 2006; 43(3):357-64. DOI: 10.1086/505217. View

19.

Doerig C, Tobin A . Parasite protein kinases: at home and abroad. Cell Host Microbe. 2010; 8(4):305-7. DOI: 10.1016/j.chom.2010.10.002. View

20.

Johner A, Kunz S, Linder M, Shakur Y, Seebeck T . Cyclic nucleotide specific phosphodiesterases of Leishmania major. BMC Microbiol. 2006; 6:25. PMC: 1431542. DOI: 10.1186/1471-2180-6-25. View